Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00487799
Status:
WITHDRAWN
Last Update Posted:
2009-07-20
First Post:
2007-06-15
Brief Title:
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
Sponsor:
Facet Biotech
Organization:
Facet Biotech
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
Status:
WITHDRAWN
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Facet no longer has ownership of ularitide
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the maximum tolerated dose MTD of ularitide in the treatment of subjects hospitalized with symptomatic acute decompensated heart failure ADHF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None